动物造模,皮肤不良反应 z-bio 2022-02-01 831

　　Purpose: Erlotinib is a new type of targeted drug for the treatment of non-small cell lung cancer. It has been widely used in clinical practice in recent years, but it has many side effects. Among them, rash is the most common and difficult for patients to accept. The purpose of this study is to observe the changes in the epidermis, pathology, immunohistochemistry and other aspects of mice before and after the application of Tarceva, replicate the animal model of rash caused by Tarceva, and provide a model for the clinical treatment of skin rashes with topical drugs.

　　Method: 20 BALB/c female mice were used and randomly divided into 4 groups. The experimental group (groups Ⅱ, Ⅲ, and Ⅳ) was given 100 mg/kg Tarceva solution with a concentration of 10 g/L, and the control group (group Ⅰ) was given an equal volume of deionized water once a day. Hair removal was performed on the head, neck, back and waist of the mice 24 hours before the administration. After the experiment, the skin on the neck, back and waist was cut and observed in the experimental group and the control group in terms of gross skin, pathological section, immunohistochemistry, etc. Change.

　　Results: (1) The four groups of mice had statistically significant differences in the number of days of hair regeneration, days of complete hair regeneration, desquamation time, time of appearance of rash, number of pore dilation, etc. (P<0.01 or P<0.05) ki67:="" there="" was="" no="" statistically="" significant="" difference="" between="" the="" four="" groups="" p="">0.05).

　　Conclusion: (1) This experiment confirms the opinions of many researchers that "the rash caused by EGFRIs is an inflammatory response"; (2) The rash model is reliable, practical, reproducible, and suitable for animals with rashes caused by EGFRIs. The large-scale establishment of "models" can be promoted for clinical, experimental, and research purposes.